Abstract
Alzheimers disease (AD) is the leading cause of dementia in the elderly. Although the etiology of AD remains unclear, microglia-mediated neuroinflammation is believed to play an important role in its pathogenesis. Microglial activation occurs in AD and is characterized by apparent phagocytic activity and by increased production and secretion of several cytokines, chemokines, reactive oxygen and nitrogen species, prostaglandin (PG)E2, and neurotrophic factors. Microglial activation can be neuroprotective through the release of neurotrophic factors and by phagocytosing Aβ, a critical neurotoxic component in AD brain. Concurrently, microglial activation causes elevated inflammatory responses that lead to paracrine damage to neurons. Therefore, a well-controlled microglial activation that diminishes microglial-mediated oxidative damage while promoting neuronal protection may be the key for AD therapy. Peroxisome proliferator-activated receptor gamma (PPARγ) has recently gained increasing attention in AD due to its function as a molecular target for nonsteroidal anti-inflammatory drugs (NSAIDs). In this review, we will discuss the role of PPARγ in microglial innate immunity in AD and how pharmacological manipulation of microglial activation using PPARγ ligands might facilitate the treatment of AD.
Keywords: Alzheimer's disease, microglial activation, PPARγ, neuroinflammation, β-amyloid, therapy
Current Medicinal Chemistry
Title: Modulation of Microglial Innate Immunity in Alzheimers Disease by Activation of Peroxisome Proliferator-activated Receptor Gamma
Volume: 16 Issue: 6
Author(s): Feng-Shiun Shie, Mary Nivison, Pei-Chien Hsu and Thomas J. Montine
Affiliation:
Keywords: Alzheimer's disease, microglial activation, PPARγ, neuroinflammation, β-amyloid, therapy
Abstract: Alzheimers disease (AD) is the leading cause of dementia in the elderly. Although the etiology of AD remains unclear, microglia-mediated neuroinflammation is believed to play an important role in its pathogenesis. Microglial activation occurs in AD and is characterized by apparent phagocytic activity and by increased production and secretion of several cytokines, chemokines, reactive oxygen and nitrogen species, prostaglandin (PG)E2, and neurotrophic factors. Microglial activation can be neuroprotective through the release of neurotrophic factors and by phagocytosing Aβ, a critical neurotoxic component in AD brain. Concurrently, microglial activation causes elevated inflammatory responses that lead to paracrine damage to neurons. Therefore, a well-controlled microglial activation that diminishes microglial-mediated oxidative damage while promoting neuronal protection may be the key for AD therapy. Peroxisome proliferator-activated receptor gamma (PPARγ) has recently gained increasing attention in AD due to its function as a molecular target for nonsteroidal anti-inflammatory drugs (NSAIDs). In this review, we will discuss the role of PPARγ in microglial innate immunity in AD and how pharmacological manipulation of microglial activation using PPARγ ligands might facilitate the treatment of AD.
Export Options
About this article
Cite this article as:
Shie Feng-Shiun, Nivison Mary, Hsu Pei-Chien and Montine J. Thomas, Modulation of Microglial Innate Immunity in Alzheimers Disease by Activation of Peroxisome Proliferator-activated Receptor Gamma, Current Medicinal Chemistry 2009; 16 (6) . https://dx.doi.org/10.2174/092986709787458399
DOI https://dx.doi.org/10.2174/092986709787458399 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Brain Gangliosides in Alzheimer’s Disease: Increased Expression of Cholinergic Neuron-Specific Gangliosides
Current Alzheimer Research Anticancer Agents: VTA or VDA
Current Bioactive Compounds Dogs with Cognitive Dysfunction Syndrome: A Natural Model of Alzheimer’s Disease
Current Alzheimer Research Psychobiological Model of Personality: Guidelines for Pharmacotherapy of Personality Disorder
Current Psychopharmacology Generation and Transplantation of Dopaminergic Neurons Derived from Embryonic Stem Cells
Current Stem Cell Research & Therapy Pathologically-Activated Therapeutics for Neuroprotection: Mechanism of NMDA Receptor Block by Memantine and S-Nitrosylation
Current Drug Targets The Correlations between Postmortem Brain Pathologies and Cognitive Dysfunction in Aging and Alzheimer's Disease
Current Alzheimer Research CCL2-CCR2 Signaling in Disease Pathogenesis
Endocrine, Metabolic & Immune Disorders - Drug Targets Optimal Treatment of Severe Community-Acquired Pneumonia
Current Respiratory Medicine Reviews New Approaches in the Diagnosis of Atherosclerosis and Treatment of Cardiovascular Disease
Recent Patents on Cardiovascular Drug Discovery Neuroimaging Features of Acquired Metabolic and Toxic Encephalopathies
Current Medical Imaging Novel Iodinated Hydrazide-hydrazones and their Analogues as Acetyl- and Butyrylcholinesterase Inhibitors
Current Topics in Medicinal Chemistry Differences in Functional Brain Activation and Hippocampal Volume Among Amnestic Mild Cognitive Impairment Subtypes
Current Alzheimer Research Neuroprotective Appraisal of Methanolic Extract of Flowers of Nerium oleander in a Non Classical Rat Model of Alzheimer Disease
The Natural Products Journal In Vitro Models of the Blood-Brain Barrier: When to Use Which?
Current Medicinal Chemistry - Central Nervous System Agents Vitamin D and Subjective Memory Complaint in Community-Dwelling Older Adults
Current Alzheimer Research Hybrid-Based Multi-Target Ligands for the Treatment of Alzheimer's Disease
Current Topics in Medicinal Chemistry Amyloid Formation in Surfactants and Alcohols: Membrane Mimetics or Structural Switchers?
Current Protein & Peptide Science The Safety, Tolerability, Pharmacokinetics and Cognitive Effects of GSK239512, a Selective Histamine H<sub>3</sub> Receptor Antagonist in Patients with Mild to Moderate Alzheimer’s Disease: A Preliminary Investigation
Current Alzheimer Research Cerebral White Matter Lesions, Risk of Stroke and Cerebrovascular Protection with Angiotensin Receptor Blockers
Current Drug Therapy